Cor Medix Inc. CRMD
We take great care to ensure that the data presented and summarized in this overview for CorMedix Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CRMD
View all-
Black Rock Inc. New York, NY3.55MShares$33.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.38MShares$32.1 Million0.0% of portfolio
-
Paul Singer Elliott Investment Management L.P. | West Palm Beach, Fl2.87MShares$27.2 Million0.14% of portfolio
-
State Street Corp Boston, MA1.45MShares$13.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.39MShares$13.2 Million0.0% of portfolio
-
First Turn Management, LLC Del Mar, CA1.02MShares$9.69 Million1.48% of portfolio
-
Northern Trust Corp Chicago, IL512KShares$4.85 Million0.0% of portfolio
-
J. Goldman & CO LP New York, NY457KShares$4.34 Million0.1% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY446KShares$4.24 Million0.0% of portfolio
-
Morgan Stanley New York, NY399KShares$3.79 Million0.0% of portfolio
Latest Institutional Activity in CRMD
Top Purchases
Top Sells
About CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Insider Transactions at CRMD
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 17
2025
|
Robert A Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+40.98%
|
-
|
|
Jan 17
2025
|
Alan W Dunton Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+38.31%
|
-
|
|
Jan 17
2025
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
23,977
-4.84%
|
$287,724
$12.17 P/Share
|
|
Jan 17
2025
|
Joseph Todisco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
187,500
+27.45%
|
-
|
|
Jan 17
2025
|
Steven W Lefkowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+19.92%
|
-
|
|
Jan 17
2025
|
Myron Kaplan Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+12.44%
|
-
|
|
Jan 17
2025
|
Janet Dillione Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+24.16%
|
-
|
|
Jan 17
2025
|
Gregory Scott Duncan Director |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+50.0%
|
-
|
|
Jan 10
2025
|
Erin Mistry EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,689
-5.33%
|
$62,579
$11.19 P/Share
|
|
Jan 10
2025
|
Joseph Todisco Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,829
-5.47%
|
$196,119
$11.19 P/Share
|
|
Jan 10
2025
|
Matthew T David Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,515
-6.4%
|
$71,665
$11.19 P/Share
|
|
Jan 10
2025
|
Elizabeth Masson Hurlburt EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
5,790
-4.76%
|
$63,690
$11.19 P/Share
|
|
Jan 02
2025
|
Kaufman Beth Zelnick Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,844
-9.01%
|
$94,752
$8.22 P/Share
|
|
Jan 02
2025
|
Kaufman Beth Zelnick Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+39.96%
|
-
|
|
Jan 02
2025
|
Matthew T David Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,648
-7.83%
|
$69,184
$8.22 P/Share
|
|
Jan 02
2025
|
Matthew T David Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+36.14%
|
-
|
|
Jan 02
2025
|
Elizabeth Masson Hurlburt EVP |
SELL
Payment of exercise price or tax liability
|
Direct |
11,378
-8.56%
|
$91,024
$8.22 P/Share
|
|
Jan 02
2025
|
Elizabeth Masson Hurlburt EVP |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+39.7%
|
-
|
|
Jan 02
2025
|
Erin Mistry EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,830
-6.84%
|
$62,640
$8.22 P/Share
|
|
Jan 02
2025
|
Erin Mistry EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+35.31%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 638K shares |
|---|---|
| Open market or private purchase | 15.1K shares |
| Exercise of conversion of derivative security | 153K shares |
| Payment of exercise price or tax liability | 133K shares |
|---|---|
| Open market or private sale | 140K shares |